Brind.

UBS reiterated a Buy rating on Acadia Healthcare, noting that the company could benefit from Trump-era tariffs.

1 report, 1 independent Updated Jul 10

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Acadia Healthcare UBS

Keep exploring

The entities involved

Acadia Healthcare
multinational behavioral healthcare provider

Nothing else this week.
UBS
Swiss multinational investment bank and financial services company
- The Trump administration threatens tariffs on Switzerland, leading Switzerland to seek a new trade agreement with the US.Mon 00:13
- Following the acquisition of Credit Suisse, the Swiss parliament proposed new banking regulations for UBS.Sun 10:25

Related events

Acadia Healthcare and Castle Biosciences are being compared as healthcare companies.Sep 15

Coverage

Newest first; wire copies grouped

Jul 10Insider MonkeyUBS Reiterates a Buy Rating on Acadia Healthcare (ACHC) With a $45 Price Target Acadia Healthcare Company, Inc. (NASDAQ:ACHC) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. In a